Cargando…
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study
BACKGROUND: Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. Pitavastatin has less drug-drug interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected indivi...
Autores principales: | Wongprikorn, Asita, Sukasem, Chonlaphat, Puangpetch, Apichaya, Numthavej, Pawin, Thakkinstian, Ammarin, Kiertiburanakul, Sasisopin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909195/ https://www.ncbi.nlm.nih.gov/pubmed/27304841 http://dx.doi.org/10.1371/journal.pone.0157531 |
Ejemplares similares
-
Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2023) -
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand
por: Bushyakanist, Asalaysa, et al.
Publicado: (2015) -
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
por: Damronglerd, Pansachee, et al.
Publicado: (2015) -
Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone
por: Vanwong, Natchaya, et al.
Publicado: (2021) -
Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand
por: Sungkanuparph, Somnuek, et al.
Publicado: (2012)